Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMO | Q99835 | 15/20 | 0.41 |
| ▸ | MMP1 | P03956 | 1/20 | 0.39 |
| ▸ | MMP3 | P08254 | 1/20 | 0.39 |
| ▸ | MMP7 | P09237 | 1/20 | 0.39 |
| ▸ | MMP9 | P14780 | 1/20 | 0.39 |
| ▸ | MMP13 | P45452 | 1/20 | 0.39 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5653850 | 1.00 | SMO (0.41) | SMOMMP1MMP3MMP7MMP9 | |
| SCHEMBL5347198 | 0.86 | MMP1 (0.41) | SMOMMP1MMP3MMP7MMP9 | |
| SCHEMBL5341355 | 0.86 | MMP1 (0.41) | SMOMMP1MMP3MMP7MMP9 | |
| SCHEMBL5323845 | 0.81 | MMP1 (0.49) | SMOMMP1MMP3MMP7MMP9 | |
| SCHEMBL5319379 | 0.81 | MMP1 (0.49) | SMOMMP1MMP3MMP7MMP9 | |
| SCHEMBL5322548 | 0.81 | MMP1 (0.43) | SMOMMP1MMP3MMP7MMP9 | |
| SCHEMBL5326286 | 0.81 | MAPT (0.49) | MMP1MMP3MMP7MMP9MMP13 | |
| SCHEMBL5322626 | 0.81 | MAPT (0.49) | MMP1MMP3MMP7MMP9MMP13 | |
| SCHEMBL5652538 | 0.80 | SMO (0.45) | SMOMMP1MMP3MMP7MMP9 | |
| SCHEMBL5653521 | 0.79 | SLC6A7 (0.47) | SMOMMP1MMP3MMP7MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070259879-A1 | Piperazine and piperidine biaryl derivatives | TRIMERIS, INC. | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259879-A1 | Piperazine and piperidine biaryl derivatives | CYP3A5, CYP3A43, CCR5 | SMO 3378/4885MMP1 3234/4885MMP3 1583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.